EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study

Shiwei Guo, Heshui Wu, Suizhi Gao, Weiyu Hu, Hui Jiang, Yun Bian, Yijie Zhang, Bo Li, Gang Li, Xuefeng Xu, Min Wang, Chenglin Zhu und 5 weitere

Journal of Neuroendocrinology · 2024-12 · 36 (12)

DOI: 10.1111/jne.13442 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 10.09.2024. Verfasst von Shiwei Guo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Hepatobiliary Surgery, Changhai Hospital, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Octreotide, Pancreatic Neoplasms, Neuroendocrine Tumors, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant therapy for pancreatic neuroendocrine tumors (PanNETs) after radical resection lacks evidence‐based data and remains controversial. This study aimed to validate whether long‐acting octreotide is a potential candidate for adjuvant therapy in patients with G2 PanNETs at high recurrence risk by clustering real‐world data. A retrospective review of patients with nonmetastatic grade 2 PanNETs who underwent radical resection at six research centers between 2008 and 2020 was conducted. Propensity score matching and inverse probability of treatment weight analysis were used to control confounding factors. Overall, 357 patients (octreotide group, n = 82; control group, n = 275) were analyzed. Kaplan–Meier survival analyses showed that the octreotide group had longer disease‐free survival (DFS) compared with the control group (36 months: 93.3% vs. 79.0%, p = .0124; 60 months: 71% vs. 67.6%, p = .0596, respectively), as well as overall survival (OS) (60 months: 98% vs. 83.8%, p = .0117, respectively). Multivariate analyses indicated that octreotide long‐acting repeatable (LAR) adjuvant therapy was associated with higher OS ( p = .0270) at 60 months. Propensity score matching analysis showed that octreotide adjuvant therapy was associated with higher DFS ( p = .0455) and OS ( p = .0190) at 60 months. Similar results were obtained via inverse probability of treatment weight analysis. Subgroup analysis indicated that octreotide LAR was associated with a high DFS in patients with lymph node metastasis or Ki‐67

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OctreotidePancreatic NeoplasmsNeuroendocrine TumorsNeoplasm Recurrence, LocalAntineoplastic Agents, HormonalHumansFemaleMaleRetrospective StudiesMiddle AgedAgedChemotherapy, AdjuvantAdultTreatment OutcomeDisease-Free Survival

Stichwörter der Autor:innen

G2adjuvant therapyoctreotidepancreatic neuroendocrine tumorsradical resection

Substanzen

OctreotideAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Pancreatic Hepatobiliary Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Department of Pancreatic Surgery, Union Hospital, Tognji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Hepatopancreatobiliary Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Department of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Department of Radiology, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Gang Jin

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, S., Wu, H., Gao, S., Hu, W., Jiang, H., Bian, Y., Zhang, Y., Li, B., Li, G., Xu, X., Wang, M., Zhu, C., Qu, L., Huang, Q., Qin, R., Lou, W., & Jin, G. (2024). Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study. Journal of Neuroendocrinology, 36(12). https://doi.org/10.1111/jne.13442

Vancouver

Guo S, Wu H, Gao S, Hu W, Jiang H, Bian Y, et al. Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study. Journal of Neuroendocrinology. 2024;36(12). doi:10.1111/jne.13442

BibTeX
@article{Guo2024,
  author = {Guo, Shiwei and Wu, Heshui and Gao, Suizhi and Hu, Weiyu and Jiang, Hui and Bian, Yun and Zhang, Yijie and Li, Bo and Li, Gang and Xu, Xuefeng and Wang, Min and Zhu, Chenglin and Qu, Linlin and Huang, Qiang and Qin, Renyi and Lou, Wenhui and Jin, Gang},
  title = {Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study},
  journal = {Journal of Neuroendocrinology},
  year = {2024},
  volume = {36},
  number = {12},
  doi = {10.1111/jne.13442}
}
Kostenlos starten →